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Summarv
Intermittent claudication is the most frequent clinical manifestation of atherosclerosis
affecting the arteries of the lower limb. It is not uncommon in the elderly: from 2 to 57"
of the population between the ages of 55 and 75 suffer from claudication. The
characteristic symptoms are pain, cramp, or fatigue in muscles of the lower extremity
caused by walking, which are completely relieved after 2 to 5 minutes rest by
standing. Common sites of obstruction in the peripheral arterial system are the
aortoiliac arterial segment and the superficial femoropopliteal arterial segment.
General measures in the treatment of peripheral arterial occlusive disease are directed
towards reducing the rate of progression of atherosclerosis in the legs and at other
sites. This includes the reversal of risk factors, such as smoking, hyperlipidemia,
diabetes mellitus, and hypertension, and the use of antiplatelet drugs. More specific
measures directed towards improving the symptoms of claudication are exercise
programs, drugs, balloon angioplasty, and reconstructive surgery. Over the past few
decades percutaneous treatment strategies have become widely used and the success
rates have proven to be high, especially in the iliac arteries, with low complication
rates.
This thesis deals with the relative benefits and cost effectiveness of percutaneous
treatment strategies, more specifically stent placement and balloon angioplasty, for the
treatment of patients with intermittent claudication due to atherosclerosis of the iliac
arteries. In addition, this thesis addresses some methodological issues concerning
quality-ofJife and cost assessment.
General considerations concerning both the percutaneous treatment of iliac artery
occlusive disease and outcome assessment in the evaluation of medical interventions
are described in Chapter 1. In the treatment of iliac artery occlusive disease,
percutaneous transluminal angioplasty (PTA) has become an established, safe, and
effective procedure. Endovascular stent placement (i.e., a tubular metallic prosthesis
that can be placed inside arteries) was developed to overcome the limitations of PTA,
such as acute occlusion in the periprocedural period and restenosis within several
months. The reported results of endovascular stent placement have been very
promising, although the results are difficult to compare with those of angioplasty
because of differences in reporting methods and case mix across studies. Currently,
stent placement is commonly used to treat iliac artery occlusive disease if intra-arterial
pressure measurements or angiographic appearance indicate that the results of iliac
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balloon angioplasty are suboptimal. However, stents are increasingly being placed
primarily. Although placing a stent is expensive, a potential advantage of primary
stent placement is that initial and long-term results may be better than those of PTA or
secondary stenting. A prospective randomized clinical trial, the Dutch Iliac Stent Trial,
was initiated to compare primary stent placement with stent placement after PTA if
the results of PTA were suboptimal (defined as a residual pressure gradient of 10 mm
Hg or more, with vasodilatation, across the treated site). In addition to the medical
effectiveness, quality-of-life and cost outcomes were also assessed and a cost-
effectiveness analysis was performed. In assessing quality-of-life and cost outcomes
we encountered methodological problems, which we investigated further.
A meta-analysis of cohort studies reporting results of PTA and stent placement to
treat aortoiliac occlusive disease was performed with adjustment for differences in
case mix and reporting methods (Chapter 2). Six PTA and 8 stent studies published in
1990 or later were included in the analysis. Because risk factors and immediate
procedure results were not uniformly defined or measured under identical conditions,
a random-effects model was used to combine these proportions. Furthermore, to pool
patency results, a meta-analysis technique was used with pooling of life-table data
with and without adjustment for covariates (i.e., patient characteristics with prognostic
value in predicting failure). The results demonstrated that after treatment the mean
ankle-brachial index in the stent studies improved significantly more compared with
that in the PTA studies (mean ankle-brachial indices after treatment 0.87 versus 0.76,
respectively; p=0.03). The immediate technical success rate was higher after stent
placement (96%) than after PTA (97%), although the difference was not significant. The
complication rates and the mortality rates of stent placement and PTA did not differ
significantly. Following PTA, the  -year primary patency results were 65% for stenoses
versus 54'/" for occlusions in the treatment of claudication and 53"/" for stenoses and
44'/" for occlusions in the treatment of critical ischemia. Following stent placement, the
4-year primary patency results werc77"/" for stenoses versus 67"/" for occlusions in the
treatment of claudication and 67"/" f.or stenoses versus 53"/" for occlusions in the
treatment of critical ischemia. The risk of long-term failure was reduced by 39"h after
stent placement compared with PTA. These results suggest that in the treatment of
iliac artery occlusive disease, stent placement is superior to PTA alone. However, the
costs, quality of life, and clinical effectiveness associated with stent placement
remained unclear, with respect to primary stent placement and stent placement after
PTA (if a failure occurred) and also in comparison with PTA.
In chapters 3, 4,5, and 6 the quality of life of a health state with intermittent
claudication and the costs of the percutaneous treatment strategies were assessed. The
methodology to assess these outcomes, however, is not straightforward, e.g., costs and
quality of life can be assessed with various measures and from various viewpoints. As
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of patients with intermittent claudication is described in Chapter 3. Quality of life was
assessed with a health status measure (the RAND36-Item Health Survey 1.0 (RAND-
36)) and several valuational measures (i.e., time tradeoff, standard gamble, rating
scale, McMaster health-utilities index) and the relationships between the health-status
measure and the valuational measures were assessed. Because of the practical
difficulties related to the assessment of time-tradeoff values and standard-gamble
utilities, our long-term goal is to derive a predictive instrument for value and utility
estimation based on answers to descriptive health-status questionnaires. All quality-of-
Iife measures showed reduced quality of life in patients with intermittent claudication.
The results demonstrated that the mean values of the scores on all RAND-35 health
dimensions were significantly lower (i.e., implying poorer functioning and greater role
limitations) compared with the mean values of the scores obtained from a random
sample of the general population (matched for age and gender). The relationships
between the RAND-36 dimensions and the values and utilities varied from poor to
moderate. Conventional multiple regression analysis demonstrated that the health-
status dimensions explained only 28'/. and 14'/" of the variance in the time tradeoff and
standard gamble scores, respectively, and 62Y" and 53% of the variance in the
McMaster health utilities index and rating-scale scores, respectively. These results
suggest that answers to descriptive health-status questions cannot reliably predict
standard-gamble utilities or time-tradeoff values.
The poor relationships between the standard-gamble utilities and the health-status
scores, however, may be attributable to heterogeneity among patients in the weights
they assign to different health-status dimensions. It seems plausible that certain
health-status dimensions, e.9., bodily pain or physical functioning, are more important
for some patients than for others. The study in which we investigated this hypothesis
is described in Chapter 4. The study population was the same as the one of the study
described in chapter 3. The assumption that the population consisted of two separate
classes yielded superior representation of the data. The method of latent-class analysis
was used to estimate the unknown parameters and class memberships. It was
demonstrated that different health-status dimensions occurred in the regression
equations of the two classes and the overall explained standard-gamble variance was
49%, which was much higher than the percentages of utility explained by health-status
dimensions so far. Thus, these results suggest that patients with intermittent
claudication belong to a variety of classes, all with class-specific relationships between
the standard-gamble utility and the RAND-36 health-status dimensions.
Finally, a cost-effectiveness analysis from the societal perspective requires societal
preferences for the health state intermittent claudication. Because it was not feasible to
use existing methods to obtain preferences from a general population sample, we
developed a new method using a single binary standard-gamble question.
Furthermore, we assessed the societal preference for the health state amputation due
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to peripheral arterial occlusive disease and investigated the difference between generic
and disease-specific vignettes. This study is described in Chapter 5. A random sample
of the general population in the United States was randomly divided into L0
subgroups with a different mortality risk for each subgroup in the standard-gamble
question. The mean utility was estimated by the area above the proportional
distribution of responses indicating acceptance of the gamble. In addition, each group
was subdivided into two subgroups responding to vignettes with either a general
description or a more disease-specific description of the health states. Mean societal
utilities for intermittent claudication were demonstrated to be similar to the mean
utilities obtained from patients with intermittent claudication. Although the validity
and reliability need further testing, our results suggest that the binary standard-
gamble question can be used in the general population to obtain societal preferences
for health states. Furthermore/ the results from our study suggest that disease-specific
descriptions yield lower utilities than do generic descriptions of health states.
ln Chapter 6 the costs of the percutaneous treatment strategies were assessed from
various viewpoints in different countries. In practice, many different approaches are
used to assess costs. Possible differences caused by different methodologies may have
major implications for policy making. To investigate the results of different
methodologies and the generalizability across countries, we assessed costs from the
perspectives of the interventional radiology department, the hospital, the patient, and
the health care system both in the Netherlands and in the United States. We used a
cost-accounting method and charges to estimate the costs. It was demonstrated that
actual costs were not significantly different from charges in the Netherlands. In the
United States, however, charges were significantly higher compared with actual costs.
Furthermore, by performing the cost analysis in both countries we demonstrated that
reported costs are not by definition generalizable across countries. However, by doing
a cost analysis of various cost components across countries, cost-saving strategies may
be identified. We concluded that cost analyses may yield different results depending
on the chosen perspective and country.
The results of the meta-analysis, quality-of-life assessment, cost assessment, and
the other results of the Dutch Iliac Stent Trial were included in a cost-effectiveness
analysis comparing stent placement and PTA for iliac artery occlusive disease (Chapter
7). A Markov decision model was developed and the analysis was performed from a
societal perspective. The baseline analysis considered 60-year-old male patients with
lifestyleJimiting claudication due to stenoses in the iliac arteries for whom a
percutaneous intervention was indicated. A sensitivity analysis was performed using
different costs, quality of life, age, sex, disease severity, and lesion type. The results
demonstrated that primary stent placement compared with selective stent placement
yielded no additional benefits and was more expensive ($957). Selective stent
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Outcome assessment of the percutaneous treatment of iliac artery occlusiae disease
long-term failure 0.51) and quality-adjusted life expectancy (0.2 QALYs gained), and
an incremental cost-effectiveness ratio below $20,000 per QALY gained.
The main conclusion (see also Chapter 8) of the outcome assessment of
percutaneous treatment in iliac artery occlusive disease is that in the treatment of
patients with claudication and a stenosis, primary stent placement yields no additional
benefits and is more expensive compared with stent placement as an adjunct to PTA.
In addition, our results suggest that the gain in effectiveness of selective stent
placement cornpared with PTA alone justifies the additional costs. In the treatment of
patients with critical ischemia or an occlusion, the role of primary stent placement as
opposed to selective stent placement remains to be elucidated. Finally, although we
found that differences in quality-of-life outcomes and costs did not influence the
clinical decision in our study, providers, payers, and policy makers need to be aware
of the methods used to assess quality of life and costs in cost-effectiveness analysis in
order to make informed decisions.
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